Company: ABBV
Filing Date: 2025-03-24
Form Type: DEF 14A
Source: 0001558370-25-003537
Chunk: 76

Company: AbbVie Inc.
Filing Date: 2025-03-24
Form: DEF 14A
Chunk 76
---
 Paid” to Company-Selected Measure (Adjusted Diluted EPS) AbbVie’s annualized adjusted diluted EPS was $9.76 in 2020, $11.83 in 2021, $13.77 in 2022, $11.11 in 2023 and $10.12 in 2024. Mr. Michael’s “compensation actually paid” was approximately $33 million in 2024. Mr. Gonzalez’s “compensation actually paid” was approximately $47 million, $66 million, $67 million, $35 million and $68 million in the corresponding years and the average “compensation actually paid” to AbbVie’s other NEOs (see footnote (c) to pay versus performance table) was approximately $23 million, $24 million, $20 million, $12 million and $20 million in each of the corresponding years. While AbbVie uses numerous financial and non-financial performance measures for the purpose of evaluating performance for our compensation programs, we have determined that adjusted diluted EPS is the financial performance measure that, in AbbVie’s assessment, represents the most important performance measure (that is not otherwise required to be disclosed in the table) used to link compensation actually paid to NEOs, for the most recently completed fiscal year, to AbbVie’s performance. AbbVie places significant emphasis on achieving positive EPS outcomes because it reflects strong operating dynamics in the underlying business, which is imperative for sustained long-term growth. Most Important Performance Measures The performance measures that AbbVie uses in our executive compensation program are selected based on the objective of incentivizing NEOs to achieve long-term, sustainable growth in stockholder value. As required by 68 | 2025 Proxy Statement

| ​ | ​                      |
| ​ | EXECUTIVE COMPENSATION |

Item 402(v) of Regulation S-K, we have identified the following financial performance measures as being the most important in linking actual compensation paid to executives to AbbVie’s performance.

| Adjusted Diluted Earnings Per Share          |
| Adjusted Relative Return on Invested Capital |
| Adjusted Return on Assets                    |
| Non-GAAP Income Before Taxes                 |
| Non-GAAP Operating Margin                    |
| Platform Revenue                             |
| Total Shareholder Return                     |

Potential Payments upon Termination or Change in Control POTENTIAL PAYMENTS UPON TERMINATION – GENERALLY In accordance with AbbVie’s longstanding practice, the company has not entered into employment agreements with its NEOs. NEOs do not have any